NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE6605 Query DataSets for GSE6605
Status Public on Jan 16, 2007
Title Expression data from Metastatic Prostate Tumor
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Prostate cancer is characterized by heterogeneity in the clinical course that often does not to correlate with morphologic features of the tumor. Metastasis reflects the most adverse outcome of prostate cancer, and to date there are no reliable morphologic features or serum biomarkers that can reliably predict which patients are at higher risk of developing metastatic disease. Understanding the differences in the biology of metastatic and organ confined primary tumors is essential for developing new prognostic markers and therapeutic targets. Using Affymetrix oligonucleotide arrays, we analyzed gene expression profiles of 24 androgen-ablation resistant metastatic samples obtained from 4 patients and a previously published dataset of 64 primary prostate tumor samples. Differential gene expression was analyzed after removing potentially uninformative stromal genes, addressing the differences in cellular content between primary and metastatic tumors. The metastatic samples are highly heterogeneous in expression; however, differential expression analysis shows that 415 genes are upregulated and 364 genes are downregulated at least 2 fold in every patient with metastasis. The expression profile of metastatic samples reveals changes in expression of a unique set of genes representing both the androgen ablation related pathways and other metastasis related gene networks such as cell adhesion, bone remodeling and cell cycle. The differentially expressed genes include metabolic enzymes, transcription factors such as Forkhead Box M1 (FoxM1) and cell adhesion molecules such as Osteopontin (SPP1). We hypothesize that these genes have a role in the biology of metastatic disease and that they represent potential therapeutic targets for prostate cancer.
Keywords: disease state analysis
 
Overall design Using Affymetrix oligonucleotide arrays, we analyzed gene expression profiles of 24 androgen-ablation resistant metastatic samples obtained from 4 patients and a previously published dataset of 64 primary prostate tumor samples. Differential gene expression was analyzed after removing potentially uninformative stromal genes, addressing the differences in cellular content between primary and metastatic tumors.
 
Contributor(s) Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA
Citation(s) 17430594, 17071602
Submission date Dec 22, 2006
Last update date Dec 13, 2018
Contact name Federico Alberto Monzon
E-mail(s) famonzon@tmhs.org
Organization name The Methodist Hospital
Department Pathology
Lab Molecular Diagnostics
Street address 6565 Fannin St, MS205
City Houston
State/province TX
ZIP/Postal code 77030
Country USA
 
Platforms (3)
GPL92 [HG_U95B] Affymetrix Human Genome U95B Array
GPL93 [HG_U95C] Affymetrix Human Genome U95C Array
GPL8300 [HG_U95Av2] Affymetrix Human Genome U95 Version 2 Array
Samples (75)
GSM152856 Metastatic prostate tumor samples in liver from patient FB561 FB561_5FU95Av2
GSM152857 Metastatic prostate tumor samples recurrent in prostate from patient FB561 FB561_4HU95Av2
GSM152858 Metastatic prostate tumor samples in liver from patient EB666 EB666_1G+1HU95Av2
This SubSeries is part of SuperSeries:
GSE6919 Expression Data from Normal and Prostate Tumor Tissues
Relations
BioProject PRJNA104175

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE6605_RAW.tar 194.5 Mb (http)(custom) TAR (of CEL)

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap